• ?23.5 million in Cash and Cash equivalents as of March 31,
reflecting the first positive effects of the restructuring plan
• ?30 million in additional funding secured
Strasbourg, France, April 21, 2016, 06:00 pm CET – Transgene (Euronext Paris: TNG), a company focused on discovering and developing targeted immunotherapies for the treatment of cancer and infectious diseases, today published a business update for the quarter ending March 31, 2016.
During the first quarter of 2016, revenue from collaborative and licensing agreements was mainly composed of research services and royalties.
As of March 31, 2016, government financing for research expenditures mainly consisted of 25% of the research tax credit expected for 2016 (?1.6 million in the first quarter of 2016 versus ?2.0 million over the same period in 2015). This decrease was due to lower eligible research and development expenses, explained by the restructuring of the Company.
For more information: http://www.transgene.fr/?page_id=10788
Si le fichier PDF ne s'affiche pas ou pour le télécharger, cliquez ici.
Pour consulter le fichier PDF en intégralité, cliquez ici.
|TRANSGENE||Euronext Paris||3.22 (c)||-1.23%||56 883|